David Sciberras

2.1k total citations
31 papers, 1.5k citations indexed

About

David Sciberras is a scholar working on Cellular and Molecular Neuroscience, Psychiatry and Mental health and Molecular Biology. According to data from OpenAlex, David Sciberras has authored 31 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Cellular and Molecular Neuroscience, 8 papers in Psychiatry and Mental health and 7 papers in Molecular Biology. Recurrent topics in David Sciberras's work include Neuroscience and Neuropharmacology Research (6 papers), Epilepsy research and treatment (5 papers) and Pharmaceutical studies and practices (4 papers). David Sciberras is often cited by papers focused on Neuroscience and Neuropharmacology Research (6 papers), Epilepsy research and treatment (5 papers) and Pharmaceutical studies and practices (4 papers). David Sciberras collaborates with scholars based in United States, United Kingdom and Belgium. David Sciberras's co-authors include Arturo G. Porras, Robert Tipping, Kenneth C. Lasseter, Coleen M. Clineschmidt, Cynthia Guzzo, Cong Chen, Christine Furtek, Michael R. Goldberg, Barry J. Gertz and John Y‐K. Hsieh and has published in prestigious journals such as PLoS ONE, The Journal of Clinical Endocrinology & Metabolism and Biological Psychiatry.

In The Last Decade

David Sciberras

30 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Sciberras United States 19 331 272 213 204 202 31 1.5k
Agnes E. Coutinho United Kingdom 12 132 0.4× 160 0.6× 53 0.2× 213 1.0× 17 0.1× 12 1.8k
Alessandra Barassi Italy 23 208 0.6× 147 0.5× 202 0.9× 239 1.2× 9 0.0× 91 1.7k
Enrico Colli Italy 32 67 0.2× 85 0.3× 847 4.0× 105 0.5× 32 0.2× 79 2.8k
K. Herkner Austria 32 83 0.3× 62 0.2× 72 0.3× 468 2.3× 126 0.6× 98 2.7k
Chandra M. Pandey India 25 68 0.2× 87 0.3× 100 0.5× 73 0.4× 38 0.2× 48 1.6k
Bunzo Matsuura Japan 34 121 0.4× 282 1.0× 88 0.4× 670 3.3× 33 0.2× 211 3.9k
M J Harrison United Kingdom 29 210 0.6× 64 0.2× 217 1.0× 208 1.0× 22 0.1× 62 2.6k
O Oelz Switzerland 37 164 0.5× 152 0.6× 38 0.2× 574 2.8× 11 0.1× 98 4.2k
Z Spirer Israel 26 77 0.2× 76 0.3× 55 0.3× 292 1.4× 12 0.1× 113 2.2k
Christoph Baerwald Germany 27 94 0.3× 174 0.6× 169 0.8× 312 1.5× 13 0.1× 134 2.3k

Countries citing papers authored by David Sciberras

Since Specialization
Citations

This map shows the geographic impact of David Sciberras's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Sciberras with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Sciberras more than expected).

Fields of papers citing papers by David Sciberras

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Sciberras. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Sciberras. The network helps show where David Sciberras may publish in the future.

Co-authorship network of co-authors of David Sciberras

This figure shows the co-authorship network connecting the top 25 collaborators of David Sciberras. A scholar is included among the top collaborators of David Sciberras based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Sciberras. David Sciberras is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chanteux, Hugues, M. Macpherson, Christian Otoul, et al.. (2024). Overview of preclinical and clinical studies investigating pharmacokinetics and drug–drug interactions of padsevonil. Expert Opinion on Drug Metabolism & Toxicology. 20(8). 841–855.
2.
Otoul, Christian, M. Macpherson, Mark Watling, et al.. (2023). Clinical Bridging Studies and Modeling Approach for Implementation of a Patient Centric Sampling Technique in Padsevonil Clinical Development. The AAPS Journal. 26(1). 1–1. 4 indexed citations
3.
Cawthorne, Christopher, R. P. Maguire, Joël Mercier, et al.. (2021). Human biodistribution and dosimetry of [11C]-UCB-J, a PET radiotracer for imaging synaptic density. EJNMMI Physics. 8(1). 37–37. 5 indexed citations
4.
Muglia, Pierandrea, Jonas Hannestad, Christian Brandt, et al.. (2020). Padsevonil randomized Phase IIa trial in treatment-resistant focal epilepsy: a translational approach. Brain Communications. 2(2). fcaa183–fcaa183. 18 indexed citations
5.
Mertens, Nathalie, R. P. Maguire, Kim Serdons, et al.. (2019). Validation of Parametric Methods for [11C]UCB-J PET Imaging Using Subcortical White Matter as Reference Tissue. Molecular Imaging and Biology. 22(2). 444–452. 25 indexed citations
6.
Koole, Michel, June van Aalst, Nathalie Mertens, et al.. (2018). Quantifying SV2A density and drug occupancy in the human brain using [11C]UCB-J PET imaging and subcortical white matter as reference tissue. European Journal of Nuclear Medicine and Molecular Imaging. 46(2). 396–406. 72 indexed citations
7.
Michel, Anne, Sarah Rose, Michael S. Jackson, et al.. (2017). Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets. PLoS ONE. 12(8). e0182887–e0182887. 13 indexed citations
8.
Gow, Jason M., Wayne Tsuji, Gary J. Williams, et al.. (2015). Safety, tolerability, pharmacokinetics, and efficacy of AMG 403, a human anti-nerve growth factor monoclonal antibody, in two phase I studies with healthy volunteers and knee osteoarthritis subjects. Arthritis Research & Therapy. 17(1). 282–282. 22 indexed citations
9.
Eng, Waisi, John Atack, Mats Bergström, et al.. (2010). Occupancy of human brain GABAA receptors by the novel α5 subtype-selective benzodiazepine site inverse agonist α5IA as measured using [11C]flumazenil PET imaging. Neuropharmacology. 59(7-8). 635–639. 15 indexed citations
10.
Bergström, Mats, Richard Hargreaves, H. Donald Burns, et al.. (2004). Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biological Psychiatry. 55(10). 1007–1012. 152 indexed citations
11.
Calder, Nicole, Malcolm Boyce, John Posner, & David Sciberras. (2003). Clinical pharmacology studies in UK Phase 1 units: an AHPPI survey 1999–2000. British Journal of Clinical Pharmacology. 57(1). 76–79. 3 indexed citations
12.
Guzzo, Cynthia, Christine Furtek, Arturo G. Porras, et al.. (2002). Safety, Tolerability, and Pharmacokinetics of Escalating High Doses of Ivermectin in Healthy Adult Subjects. The Journal of Clinical Pharmacology. 42(10). 1122–1133. 215 indexed citations
13.
Strachan, Fiona E., David E. Newby, David Sciberras, et al.. (2002). Repeatability of local forearm vasoconstriction to endothelin‐1 measured by venous occlusion plethysmography. British Journal of Clinical Pharmacology. 54(4). 386–394. 15 indexed citations
14.
Goldberg, Michael R., David Sciberras, Marina De Smet, et al.. (2001). Influence of β‐adrenoceptor antagonists on the pharmacokinetics of rizatriptan, a 5‐HT1B/1D agonist: differential effects of propranolol, nadolol and metoprolol. British Journal of Clinical Pharmacology. 52(1). 69–76. 37 indexed citations
15.
Newby, David E., David Sciberras, Charles J. Ferro, et al.. (1999). Substance P‐induced vasodilatation is mediated by the neurokinin type 1 receptor but does not contribute to basal vascular tone in man. British Journal of Clinical Pharmacology. 48(3). 336–344. 31 indexed citations
16.
Sciberras, David, William J. Polvino, Barry J. Gertz, et al.. (1997). Initial human experience with MK-462 (rizatriptan): a novel 5=HTIDagonist. British Journal of Clinical Pharmacology. 43(1). 49–54. 28 indexed citations
17.
Newby, David E., David Sciberras, Carl M. Mendel, et al.. (1997). Intra‐arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. British Journal of Clinical Pharmacology. 43(5). 493–499. 35 indexed citations
18.
Polvino, William J., David Sciberras, K. Cerchio, et al.. (1996). PHARMACOKINETICS AND FOOD INTERACTION OF MK-462 IN HEALTHY MALES. Biopharmaceutics & Drug Disposition. 17(1). 17–24. 22 indexed citations
19.
Cockcroft, John R., David Sciberras, Michael R. Goldberg, & James M. Ritter. (1993). Comparison of Angiotensin-Converting Enzyme Inhibition with Angiotensin II Receptor Antagonism in the Human Forearm. Journal of Cardiovascular Pharmacology. 22(4). 579–584. 79 indexed citations
20.
Warren, J. B., C. T. Dollery, David Sciberras, & Michael R. Goldberg. (1991). Assessment of MK-467, a peripheral α2-adrenergic receptor antagonist, with intravenous clonidine. Clinical Pharmacology & Therapeutics. 50(1). 71–77. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Agnes E. Coutinho Breakdown of academic impact, for papers by Alessandra Barassi Breakdown of academic impact, for papers by Enrico Colli Breakdown of academic impact, for papers by K. Herkner Breakdown of academic impact, for papers by Chandra M. Pandey Breakdown of academic impact, for papers by Bunzo Matsuura Breakdown of academic impact, for papers by M J Harrison Breakdown of academic impact, for papers by O Oelz Breakdown of academic impact, for papers by Z Spirer Breakdown of academic impact, for papers by Christoph Baerwald
Rankless by CCL
2026